Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients

American Journal of Hematology

Volumn 87, Issue 7, 2012, Pages 732-733

  Maggio, Aurelio ^a   Vitrano, Angela ^b   Lucania, Gaetano ^c   Capra, Marcello ^d   Cuccia, Liana ^d   Gagliardotto, Francesco ^d   Pitrolo, Lorella ^e   Prossomariti, Luciano ^f   Filosa, Aldo ^g   Caruso, Vincenzo ^h   Gerardi, Calogera ⁱ   Campisi, Saveria ^j   Cianciulli, Paolo ^k   Rizzo, Michele ^l   D'Ascola, Giuseppe ^m   Ciancio, Angela ⁿ   Di Maggio, Rosario ^o   Calvaruso, Giuseppina ^a   Pantalone, Gaetano Restivo ^a   Rigano, Paolo ^a  

^a Ospedali Riuniti PO Cervello Palermo   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UO Medicina Trasfusionale Ospedali Riuniti   (Italy)

^d ARNAS Civico   (Italy)

^e Ospedali Riuniti Villa Sofia Cervello   (Italy)

^f Centro Regionale per la Cura delle Microcitemie   (Italy)

^g AO Cardarelli   (Italy)

^h ARNAS Garibaldi   (Italy)

ⁱ AO Umberto I ^*  (Italy)

^j UOS Centro Microcitemia   (Italy)

^k AO S Eugenio   (Italy)

^l UOC Ematologia   (Italy)

^m Centro Microcitemia   (Italy)

ⁿ Ospedale Civile Madonna delle Grazie   (Italy)

^o UNIVERSITY OF PALERMO   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE;

ADULT; CARDIOVASCULAR MAGNETIC RESONANCE; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK REDUCTION; THALASSEMIA MAJOR; TREATMENT DURATION;

ADULT; BETA-THALASSEMIA; DEFEROXAMINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEART VENTRICLES; HUMANS; IRON CHELATING AGENTS; MALE; MODELS, BIOLOGICAL; PYRIDONES; RETROSPECTIVE STUDIES; STROKE VOLUME; TIME FACTORS;

EID: 84862537752     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23219     Document Type: Letter

References (19)

1. Maggio A, Vitrano A, Capra M, et al. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: A randomized clinical trial. Br J Haematol 2009; 145: 245-254.
2. Hedeker D, Gibbons RD. Longitudinal data analysis. Hoboken, New Jersey: Wiley; 2006.
3. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006; 107: 3733-3737.
4. Telfer P, Coen PG, Christou S, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica 2006; 91: 1187-1192.
5. Maggio A, Vitrano A, Capra M, et al. Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis 2009; 42: 247-251.
6. Trachtenberg F, Vichinsky E, Haines D, et al. Iron chelation adherence to deferoxamine and deferasirox in thalassemia. Clinical Research Network. Am J Hematol 2011; 86: 433-436.
7. Wood JC, Glynos T, Thompson A, et al. Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial. Am J Hematol 2010; 85: 818-819.
8. Pepe A, Lombardi M, Positano V, et al. Evaluation of the efficacy of oral deferiprone in β-thalassemia major by multislice multiecho T2*. Eur J Haematol 2006; 76: 183-192.
9. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in β-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107: 3738-3744.
10. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo controlled, double blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007; 115: 1876-1884.
11. Pennell DJ, Carpenter JP, Roughton M, Cabantchik ZI. On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure. J Cardiovasc Magn Reson 2011; 12: 13-45.
12. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89: 1187-1189.
13. Wood JC. Diagnosis and management of transfusion iron overload: The role of imaging. Am J Hematol 2007; 82(12 Suppl.): 1132-1135.
14. Ademola AA. An appraisal of the cost benefit of magnetic resonance imaging in Nigeria Niger. Postgrad Med J 2003; 10: 251-253.
15. Shahgaldi K, Gudmudson P, Manouras A, et al. Visually estimated ejection fraction by two dimensional and triplane echocardiography is closely correlated with quantitative ejection fraction by real-time three dimensional echocardiography. Cardiovasc Ultrasound 2009; 25: 41.
16. Blondheim DS, Beeri R, Feinberg MS, et al. Reliability of visual assessment of global and segmental left ventricular function: A multicenter study by the Israeli Echocardiography Research Group. J Am Soc Echocardiogr 2010; 23: 258-264.
17. Giakoumis A, Berdoukas V, Gorsis E, Aessopos A. Comparison of echocardiographic (US) volumetry with cardiac magnetic resonance (CMR) imaging in transfusion dependent thalassemia major (TM). Cardiovasc Ultrasound 2007; 5: 24.
18. Otterstad JE, Froeland G, St John Sutton M, Holme I. Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function. Eur Heart J 1997; 18: 507-513.
19. Link G, Konijn AM, Hershko C. Cardioprotective effect of α-tocopherol, ascorbate, deferoxamine, and deferiprone: Mitochondrial function in cultured, iron-loaded heart cells. J Lab Clin Med 1999; 133: 179-188.